Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.31 |
| ▸ | SMARCA2 | P51531 | 2/20 | 0.31 |
| ▸ | SMARCA4 | P51532 | 2/20 | 0.31 |
| ▸ | PBRM1 | Q86U86 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL30467631 | 1.00 | FEN1 (0.33) | FEN1PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL24252672 | 0.95 | FEN1 (0.36) | FEN1PIK3CDPIK3CAPIK3CBPIK3CG | |
| Formic Acid SCHEMBL30467686 | 0.92 | LRRK2 (0.39) | PIK3CDPIK3CAPIK3CBPIK3CGKDM4E | |
| Formic Acid SCHEMBL25240502 | 0.92 | LRRK2 (0.39) | PIK3CDPIK3CAPIK3CBPIK3CGKDM4E | |
| SCHEMBL25250165 | 0.87 | FEN1 (0.32) | FEN1PIK3CDPIK3CAPIK3CBPIK3CG | |
| Formic Acid SCHEMBL30462828 | 0.87 | PLG (0.32) | — | |
| Formic Acid SCHEMBL25304448 | 0.87 | PLG (0.32) | — | |
| SCHEMBL24252619 | 0.87 | PDE10A (0.40) | PIK3CDPIK3CAPIK3CBPIK3CGKDM4E | |
| SCHEMBL26771374 | 0.87 | FEN1 (0.35) | FEN1PIK3CDPIK3CAPIK3CBPIK3CG | |
| Formic Acid SCHEMBL25296767 | 0.83 | KDM4E (0.30) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2024-04-04 | — | — | US | disclosed |
| EP-4185592-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | Annexon, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | FEN1 2638/4885PIK3CD 1808/4885PIK3CA 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.